Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study) (PreVail-PH2)
Sponsor: Gradient Denervation Technologies
A NA clinical study on Group 2 Pulmonary Hypertension and Heart Failure, this trial is actively recruiting participants. The trial is conducted by Gradient Denervation Technologies and has accumulated 14 data snapshots since 2024. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Recruiting NA
-
Oct 2025 — Jan 2026 [monthly]
Recruiting NA
-
Sep 2025 — Oct 2025 [monthly]
Recruiting NA
-
Apr 2025 — Sep 2025 [monthly]
Recruiting NA
-
Mar 2025 — Apr 2025 [monthly]
Recruiting NA
▶ Show 9 earlier versions
-
Feb 2025 — Mar 2025 [monthly]
Recruiting NA
-
Jan 2025 — Feb 2025 [monthly]
Recruiting NA
-
Dec 2024 — Jan 2025 [monthly]
Recruiting NA
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
-
Aug 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jul 2024 — Aug 2024 [monthly]
Recruiting NA
-
Mar 2024 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Mar 2024 [monthly]
Not Yet Recruiting NA
-
Oct 2023 — Dec 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gradient Denervation Technologies
For direct contact, visit the study record on ClinicalTrials.gov .